Skip to main content
. Author manuscript; available in PMC: 2015 Nov 12.
Published in final edited form as: Vaccine. 2014 Sep 20;32(48):6527–6536. doi: 10.1016/j.vaccine.2014.08.065

Table 2.

The immune responses of vaccine-protected (aviremic) vaccinees from present and our earlier published studies.

Vaccine-protected RM (Undetectable viremia) Challenge virus Virus-specific immune responses (week 0) Ref
Cellular IFN-γ ELISPOT (Total SFU/106 PBMC) Humoral Challenge virus-specific nAb titer (IC50, TZM-bl assay)
RAt-9 SHIV-1157ip (tier 1) 3830 130 32
RRi-11 SHIV-1157ipEL-p (tier 1) 3560 3157 13
RTr-11 SHIV-1157ipEL-p (tier 1) 920 4382 13
RQe-10 SHIV-1157ipEL-p (tier 1) 520 48 12
ROb-12 SHIV-2873Nip (tier 2) 570 <20 Present study